-DOCSTART- -X- O
As -X- _ O
a -X- _ O
new -X- _ O
human -X- _ O
immunodeficiency -X- _ O
virus -X- _ O
type -X- _ O
1 -X- _ O
( -X- _ O
HIV-1 -X- _ O
) -X- _ O
vaccine -X- _ O
approach -X- _ O
, -X- _ O
the -X- _ O
live-attenuated -X- _ B-Intervention
measles -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
MV -X- _ I-Intervention
) -X- _ I-Intervention
Schwarz -X- _ I-Intervention
vaccine -X- _ I-Intervention
strain -X- _ I-Intervention
was -X- _ I-Intervention
genetically -X- _ I-Intervention
engineered -X- _ I-Intervention
to -X- _ I-Intervention
express -X- _ I-Intervention
the -X- _ I-Intervention
F4 -X- _ I-Intervention
antigen -X- _ I-Intervention
( -X- _ I-Intervention
MV1-F4 -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
F4 -X- _ O
is -X- _ O
a -X- _ O
fusion -X- _ O
protein -X- _ O
comprising -X- _ O
HIV-1 -X- _ O
antigens -X- _ O
p17 -X- _ O
and -X- _ O
p24 -X- _ O
, -X- _ O
reverse -X- _ O
transcriptase -X- _ O
and -X- _ O
Nef. -X- _ O
This -X- _ O
study -X- _ O
assessed -X- _ O
the -X- _ O
toxicity -X- _ B-Outcome
, -X- _ I-Outcome
biodistribution -X- _ I-Outcome
and -X- _ I-Outcome
shedding -X- _ I-Outcome
profiles -X- _ I-Outcome
of -X- _ O
MV1-F4. -X- _ B-Intervention
Cynomolgus -X- _ B-Patient
macaques -X- _ I-Patient
were -X- _ O
intramuscularly -X- _ B-Intervention
immunized -X- _ I-Intervention
one -X- _ I-Intervention
or -X- _ I-Intervention
three -X- _ I-Intervention
times -X- _ I-Intervention
with -X- _ I-Intervention
the -X- _ I-Intervention
highest -X- _ I-Intervention
dose -X- _ I-Intervention
of -X- _ I-Intervention
MV1-F4 -X- _ I-Intervention
intended -X- _ O
for -X- _ O
clinical -X- _ O
use -X- _ O
, -X- _ O
the -X- _ O
reference -X- _ O
( -X- _ B-Intervention
Schwarz -X- _ I-Intervention
) -X- _ I-Intervention
measles -X- _ I-Intervention
vaccine -X- _ I-Intervention
or -X- _ O
saline -X- _ B-Comparison
, -X- _ O
and -X- _ O
monitored -X- _ O
clinically -X- _ O
for -X- _ O
11 -X- _ O
or -X- _ O
85 -X- _ O
days. -X- _ O
Toxicological -X- _ O
parameters -X- _ O
included -X- _ O
local -X- _ O
and -X- _ O
systemic -X- _ O
clinical -X- _ O
signs -X- _ O
, -X- _ O
organ -X- _ O
weights -X- _ O
, -X- _ O
haematology -X- _ O
, -X- _ O
clinical -X- _ O
and -X- _ O
gross -X- _ O
pathology -X- _ O
and -X- _ O
histopathology. -X- _ O
Both -X- _ B-Outcome
vaccines -X- _ I-Outcome
were -X- _ I-Outcome
well -X- _ I-Outcome
tolerated -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
no -X- _ I-Outcome
morbidity -X- _ I-Outcome
, -X- _ I-Outcome
clinical -X- _ I-Outcome
signs -X- _ I-Outcome
or -X- _ I-Outcome
gross -X- _ I-Outcome
pathological -X- _ I-Outcome
findings -X- _ I-Outcome
observed. -X- _ I-Outcome
Mean -X- _ I-Outcome
spleen -X- _ I-Outcome
weights -X- _ I-Outcome
were -X- _ I-Outcome
increased -X- _ I-Outcome
after -X- _ I-Outcome
three -X- _ I-Outcome
doses -X- _ I-Outcome
of -X- _ I-Outcome
either -X- _ I-Outcome
vaccine -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
corresponded -X- _ I-Outcome
with -X- _ I-Outcome
increased -X- _ I-Outcome
numbers -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
sizes -X- _ I-Outcome
of -X- _ I-Outcome
germinal -X- _ I-Outcome
centers. -X- _ I-Outcome
This -X- _ O
was -X- _ O
likely -X- _ O
a -X- _ O
result -X- _ O
of -X- _ O
the -X- _ O
immune -X- _ O
response -X- _ O
to -X- _ O
the -X- _ O
vaccines. -X- _ O
Either -X- _ B-Outcome
vaccine -X- _ I-Outcome
virus -X- _ I-Outcome
replicated -X- _ I-Outcome
preferentially -X- _ I-Outcome
in -X- _ I-Outcome
secondary -X- _ I-Outcome
lymphoid -X- _ I-Outcome
organs -X- _ I-Outcome
and -X- _ I-Outcome
to -X- _ I-Outcome
a -X- _ I-Outcome
lesser -X- _ I-Outcome
extent -X- _ I-Outcome
in -X- _ I-Outcome
epithelium-rich -X- _ I-Outcome
tissues -X- _ I-Outcome
( -X- _ I-Outcome
e.g. -X- _ I-Outcome
, -X- _ I-Outcome
intestine -X- _ I-Outcome
, -X- _ I-Outcome
urinary -X- _ I-Outcome
bladder -X- _ I-Outcome
and -X- _ I-Outcome
trachea -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
liver. -X- _ I-Outcome
At -X- _ I-Outcome
the -X- _ I-Outcome
expected -X- _ I-Outcome
peak -X- _ I-Outcome
of -X- _ I-Outcome
viremia -X- _ I-Outcome
, -X- _ I-Outcome
viral -X- _ I-Outcome
RNA -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
some -X- _ I-Outcome
biological -X- _ I-Outcome
fluid -X- _ I-Outcome
samples -X- _ I-Outcome
from -X- _ I-Outcome
few -X- _ I-Outcome
animals -X- _ I-Outcome
immunized -X- _ I-Outcome
with -X- _ I-Outcome
either -X- _ I-Outcome
vaccine -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
none -X- _ I-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
samples -X- _ I-Outcome
contained -X- _ I-Outcome
infectious -X- _ I-Outcome
virus. -X- _ I-Outcome
In -X- _ O
conclusion -X- _ O
, -X- _ O
no -X- _ B-Outcome
shedding -X- _ I-Outcome
of -X- _ I-Outcome
infectious -X- _ I-Outcome
viral -X- _ I-Outcome
particles -X- _ I-Outcome
was -X- _ I-Outcome
identified -X- _ I-Outcome
in -X- _ I-Outcome
cynomolgus -X- _ I-Outcome
monkeys -X- _ I-Outcome
after -X- _ I-Outcome
injection -X- _ I-Outcome
of -X- _ I-Outcome
MV1-F4 -X- _ I-Outcome
or -X- _ I-Outcome
Schwarz -X- _ I-Outcome
measles -X- _ I-Outcome
vaccines. -X- _ I-Outcome
Furthermore -X- _ O
, -X- _ O
no -X- _ O
toxic -X- _ O
effect -X- _ O
in -X- _ O
relation -X- _ O
to -X- _ O
the -X- _ O
MV -X- _ O
vaccination -X- _ O
was -X- _ O
found -X- _ O
with -X- _ O
these -X- _ O
vaccines -X- _ O
in -X- _ O
this -X- _ O
study -X- _ O
. -X- _ O

